# Personalis, Inc.: financial statements, quarterly

PSNL · Nasdaq · CIK 1527753 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/psnl.md) · [Financials](/companies/psnl/financials.md) · [Filings](/companies/psnl/filings.md) · [Insiders](/companies/psnl/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/psnl/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [18.2](/filings/0000950170-24-122290.md) | [19.7 d](/filings/0000950170-25-029221.md) | [19.5](/filings/0000950170-25-064512.md) | [22.6](/filings/0000950170-25-102993.md) | [25.7](/filings/0001193125-25-264708.md) | [16.8 d](/filings/0001193125-26-076615.md) | [20.6](/filings/0001193125-26-211896.md) | [17.2](/filings/0001193125-26-332817.md) | [14.5](/filings/0001193125-25-264708.md) | [17.3 d](/filings/0001193125-26-076615.md) | [15.5](/filings/0001193125-26-211896.md) | [22.4](/filings/0001193125-26-332817.md) |
| Cost of revenue | $m | [14.8](/filings/0000950170-24-122290.md) | [14.5 d](/filings/0000950170-25-029221.md) | [14.0](/filings/0000950170-25-064512.md) | [14.5](/filings/0000950170-25-102993.md) | [17.0](/filings/0001193125-25-264708.md) | [12.3 d](/filings/0001193125-26-076615.md) | [13.4](/filings/0001193125-26-211896.md) | [12.4](/filings/0001193125-26-332817.md) | [12.6](/filings/0001193125-25-264708.md) | [15.4 d](/filings/0001193125-26-076615.md) | [15.2](/filings/0001193125-26-211896.md) | [17.6](/filings/0001193125-26-332817.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [16.7](/filings/0000950170-24-122290.md) | [13.6 d](/filings/0000950170-25-029221.md) | [12.8](/filings/0000950170-25-064512.md) | [13.0](/filings/0000950170-25-102993.md) | [11.7](/filings/0001193125-25-264708.md) | [11.5 d](/filings/0001193125-26-076615.md) | [12.6](/filings/0001193125-26-211896.md) | [12.4](/filings/0001193125-26-332817.md) | [12.2](/filings/0001193125-25-264708.md) | [13.1 d](/filings/0001193125-26-076615.md) | [14.5](/filings/0001193125-26-211896.md) | [16.3](/filings/0001193125-26-332817.md) |
| Selling, general and administrative | $m | [12.0](/filings/0000950170-24-122290.md) | [11.5 d](/filings/0000950170-25-029221.md) | [11.6](/filings/0000950170-25-064512.md) | [12.0](/filings/0000950170-25-102993.md) | [11.4](/filings/0001193125-25-264708.md) | [11.2 d](/filings/0001193125-26-076615.md) | [12.3](/filings/0001193125-26-211896.md) | [14.2](/filings/0001193125-26-332817.md) | [13.0](/filings/0001193125-25-264708.md) | [14.1 d](/filings/0001193125-26-076615.md) | [17.9](/filings/0001193125-26-211896.md) | [22.0](/filings/0001193125-26-332817.md) |
| Operating income | $m | [(30.8)](/filings/0000950170-24-122290.md) | [(24.0) d](/filings/0000950170-25-029221.md) | [(18.9)](/filings/0000950170-25-064512.md) | [(16.9)](/filings/0000950170-25-102993.md) | [(14.4)](/filings/0001193125-25-264708.md) | [(18.1) d](/filings/0001193125-26-076615.md) | [(17.7)](/filings/0001193125-26-211896.md) | [(21.8)](/filings/0001193125-26-332817.md) | [(23.3)](/filings/0001193125-25-264708.md) | [(25.3) d](/filings/0001193125-26-076615.md) | [(32.2)](/filings/0001193125-26-211896.md) | [(33.6)](/filings/0001193125-26-332817.md) |
| Interest expense | $m | [0.0](/filings/0000950170-24-122290.md) | [0.0 d](/filings/0000950170-25-029221.md) | [0.0](/filings/0000950170-25-064512.md) | [0.0](/filings/0000950170-25-102993.md) | [0.0](/filings/0001193125-25-264708.md) | [(0.0) d](/filings/0001193125-26-076615.md) | [0.0](/filings/0001193125-26-211896.md) | [0.0](/filings/0001193125-26-332817.md) | [0.1](/filings/0001193125-25-264708.md) | [0.1 d](/filings/0001193125-26-076615.md) | [0.0](/filings/0001193125-26-211896.md) | [0.0](/filings/0001193125-26-332817.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-122290.md) | [0.0 d](/filings/0000950170-25-029221.md) | [0.0](/filings/0000950170-25-064512.md) | [0.0](/filings/0000950170-25-102993.md) | [0.0](/filings/0001193125-25-264708.md) | [0.0 d](/filings/0001193125-26-076615.md) | [0.0](/filings/0001193125-26-211896.md) | [0.0](/filings/0001193125-26-332817.md) | [0.0](/filings/0001193125-25-264708.md) | [0.0 d](/filings/0001193125-26-076615.md) | [0.0](/filings/0001193125-26-211896.md) | [0.0](/filings/0001193125-26-332817.md) |
| Net income | $m | [(29.1)](/filings/0000950170-24-122290.md) | [(26.6) d](/filings/0000950170-25-029221.md) | [(13.0)](/filings/0000950170-25-064512.md) | [(12.8)](/filings/0000950170-25-102993.md) | [(39.1)](/filings/0001193125-25-264708.md) | [(16.4) d](/filings/0001193125-26-076615.md) | [(15.8)](/filings/0001193125-26-211896.md) | [(20.1)](/filings/0001193125-26-332817.md) | [(21.7)](/filings/0001193125-25-264708.md) | [(23.8) d](/filings/0001193125-26-076615.md) | [(30.0)](/filings/0001193125-26-211896.md) | [(31.7)](/filings/0001193125-26-332817.md) |
| Diluted EPS | $ per share | [(0.60)](/filings/0000950170-24-122290.md) | not reported | [(0.26)](/filings/0000950170-25-064512.md) | [(0.24)](/filings/0000950170-25-102993.md) | [(0.64)](/filings/0001193125-25-264708.md) | not reported | [(0.18)](/filings/0001193125-26-211896.md) | [(0.23)](/filings/0001193125-26-332817.md) | [(0.24)](/filings/0001193125-25-264708.md) | not reported | [(0.29)](/filings/0001193125-26-211896.md) | [(0.30)](/filings/0001193125-26-332817.md) |
| Basic EPS | $ per share | [(0.60)](/filings/0000950170-24-122290.md) | not reported | [(0.26)](/filings/0000950170-25-064512.md) | [(0.24)](/filings/0000950170-25-102993.md) | [(0.64)](/filings/0001193125-25-264708.md) | not reported | [(0.18)](/filings/0001193125-26-211896.md) | [(0.23)](/filings/0001193125-26-332817.md) | [(0.24)](/filings/0001193125-25-264708.md) | not reported | [(0.29)](/filings/0001193125-26-211896.md) | [(0.30)](/filings/0001193125-26-332817.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [72.2](/filings/0000950170-24-122290.md) | [57.0](/filings/0000950170-25-029221.md) | [44.0](/filings/0000950170-25-064512.md) | [47.7](/filings/0000950170-25-102993.md) | [75.8](/filings/0001193125-25-264708.md) | [91.4](/filings/0001193125-26-076615.md) | [71.0](/filings/0001193125-26-211896.md) | [53.4](/filings/0001193125-26-332817.md) | [50.0](/filings/0001193125-25-264708.md) | [124](/filings/0001193125-26-332817.md) | [73.6](/filings/0001193125-26-211896.md) | [94.0](/filings/0001193125-26-332817.md) |
| Current assets | $m | [148](/filings/0000950170-23-060255.md) | [147](/filings/0000950170-25-029221.md) | [120](/filings/0000950170-24-055607.md) | [113](/filings/0000950170-24-092883.md) | [170](/filings/0000950170-24-122290.md) | [203](/filings/0001193125-26-076615.md) | [206](/filings/0000950170-25-064512.md) | [193](/filings/0000950170-25-102993.md) | [174](/filings/0001193125-25-264708.md) | [268](/filings/0001193125-26-332817.md) | [258](/filings/0001193125-26-211896.md) | [245](/filings/0001193125-26-332817.md) |
| Total assets | $m | [227](/filings/0000950170-23-060255.md) | [225](/filings/0000950170-25-029221.md) | [195](/filings/0000950170-24-055607.md) | [186](/filings/0000950170-24-092883.md) | [240](/filings/0000950170-24-122290.md) | [270](/filings/0001193125-26-076615.md) | [273](/filings/0000950170-25-064512.md) | [259](/filings/0000950170-25-102993.md) | [243](/filings/0001193125-25-264708.md) | [334](/filings/0001193125-26-332817.md) | [325](/filings/0001193125-26-211896.md) | [312](/filings/0001193125-26-332817.md) |
| Current liabilities | $m | [32.5](/filings/0000950170-23-060255.md) | [47.2](/filings/0000950170-25-029221.md) | [31.4](/filings/0000950170-24-055607.md) | [34.1](/filings/0000950170-24-092883.md) | [36.4](/filings/0000950170-24-122290.md) | [31.1](/filings/0001193125-26-076615.md) | [29.9](/filings/0000950170-25-064512.md) | [31.7](/filings/0000950170-25-102993.md) | [36.2](/filings/0001193125-25-264708.md) | [39.6](/filings/0001193125-26-332817.md) | [39.0](/filings/0001193125-26-211896.md) | [46.4](/filings/0001193125-26-332817.md) |
| Total liabilities | $m | [75.4](/filings/0000950170-23-060255.md) | [95.7](/filings/0000950170-25-029221.md) | [74.6](/filings/0000950170-24-055607.md) | [73.2](/filings/0000950170-24-092883.md) | [73.1](/filings/0000950170-24-122290.md) | [67.3](/filings/0001193125-26-076615.md) | [66.0](/filings/0000950170-25-064512.md) | [67.9](/filings/0000950170-25-102993.md) | [71.4](/filings/0001193125-25-264708.md) | [73.0](/filings/0001193125-26-332817.md) | [70.6](/filings/0001193125-26-211896.md) | [77.0](/filings/0001193125-26-332817.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [151](/filings/0000950170-24-122290.md) | [129](/filings/0001193125-26-076615.md) | [121](/filings/0000950170-25-102993.md) | [112](/filings/0001193125-25-264708.md) | [167](/filings/0001193125-25-264708.md) | [203](/filings/0001193125-26-332817.md) | [207](/filings/0001193125-26-332817.md) | [191](/filings/0001193125-26-332817.md) | [171](/filings/0001193125-25-264708.md) | [261](/filings/0001193125-26-332817.md) | [255](/filings/0001193125-26-332817.md) | [235](/filings/0001193125-26-332817.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(16.7) d](/filings/0000950170-24-122290.md) | [(13.4) d](/filings/0000950170-25-029221.md) | [(20.4)](/filings/0000950170-25-064512.md) | [(10.7) d](/filings/0000950170-25-102993.md) | [(6.2) d](/filings/0001193125-25-264708.md) | [(7.8) d](/filings/0001193125-26-076615.md) | [(18.0)](/filings/0001193125-26-211896.md) | [(12.9) d](/filings/0001193125-26-332817.md) | [(21.8) d](/filings/0001193125-25-264708.md) | [(22.2) d](/filings/0001193125-26-076615.md) | [(22.5)](/filings/0001193125-26-211896.md) | [(25.8) d](/filings/0001193125-26-332817.md) |
| Capital expenditure | $m | [0.9 d](/filings/0000950170-24-122290.md) | [3.5 d](/filings/0000950170-25-029221.md) | [0.1](/filings/0000950170-25-064512.md) | [0.0 d](/filings/0000950170-25-102993.md) | [0.2 d](/filings/0001193125-25-264708.md) | [1.2 d](/filings/0001193125-26-076615.md) | [2.5](/filings/0001193125-26-211896.md) | [0.3 d](/filings/0001193125-26-332817.md) | [1.6 d](/filings/0001193125-25-264708.md) | [0.1 d](/filings/0001193125-26-076615.md) | [3.2](/filings/0001193125-26-211896.md) | [3.8 d](/filings/0001193125-26-332817.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [45.9](/filings/0000950170-23-060255.md) | [46.7](/filings/0000950170-24-055607.md) | [47.7](/filings/0000950170-24-092883.md) | [48.7](/filings/0000950170-24-122290.md) | [50.7](/filings/0000950170-25-064512.md) | [52.4](/filings/0000950170-25-102993.md) | [61.1](/filings/0001193125-25-264708.md) | [87.5](/filings/0001193125-26-211896.md) | [88.5](/filings/0001193125-26-332817.md) | [88.7](/filings/0001193125-25-264708.md) | [104](/filings/0001193125-26-211896.md) | [105](/filings/0001193125-26-332817.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 106,799,872 at 2026-07-29, from the cover of the [10-Q filed 2026-08-04](/filings/0001193125-26-332817.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.